Features of a new corOnavirUs infection course and optioNs therapy DEpending on the andRogenic status (FOUNDER) : androgenic status in men with COVID-19 and its relationship with the disease severity
OBJECTIVE: Analysis of androgen status in men hospitalized with a moderate COVID-19 and its relationship with the severity of the disease.
MATERIALS AND METHODS: The study included 152 males with a confirmed diagnosis of COVID-19 based on the results of a positive PCR for the SARS-CoV-2 virus and/or computed tomography of the lungs hospitalized at the MSU University Clinic due to the moderate and severe COVID-19. Examination of the level of biochemical blood parameters (CRP, creatinine, urea, glucose, total testosterone (T)); CT of the lungs. To objectify the severity of the clinical symptoms, the NEWS2 distress syndrome severity scales and the original scale for assessing the clinical condition of patients with COVID 19 (SHOCS-COVID) were used.
RESULTS: The median T level in 152 examined patients was 2.14 [1.21; 3.40] ng/ml. In patients with a T level below the median, the CRP level was more than two times higher, and the D-dimer value was almost two times higher than in patients with T level above median. The duration of treatment in the hospital was longer in men with COVID 19 and an initial T level below the median than in patients with T about the median (13 days vs 10.5 days, p=0.003). Low T level was correlated with lung damage by lung CT. After improving the clinical condition, there was a linear increase in the level of T independent of its initial level.
CONCLUSION: Among men with moderate and severe COVID-19, a decreased testosterone level is detected in 46.7% of cases. Patients with low testosterone levels on admission have more severe COVID-19. A significant increase in testosterone level was observed after successful COVID-19 treatment without any special action regarding testosterone level.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
Urologiia (Moscow, Russia : 1999) - (2021), 6 vom: 01. Dez., Seite 85-99 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Kamalov, A A [VerfasserIn] |
|---|
| Themen: |
Androgenic status |
|---|
| Anmerkungen: |
Date Completed 31.12.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM335033148 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335033148 | ||
| 003 | DE-627 | ||
| 005 | 20231225224942.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM335033148 | ||
| 035 | |a (NLM)34967512 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Kamalov, A A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Features of a new corOnavirUs infection course and optioNs therapy DEpending on the andRogenic status (FOUNDER) |b androgenic status in men with COVID-19 and its relationship with the disease severity |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 31.12.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Analysis of androgen status in men hospitalized with a moderate COVID-19 and its relationship with the severity of the disease | ||
| 520 | |a MATERIALS AND METHODS: The study included 152 males with a confirmed diagnosis of COVID-19 based on the results of a positive PCR for the SARS-CoV-2 virus and/or computed tomography of the lungs hospitalized at the MSU University Clinic due to the moderate and severe COVID-19. Examination of the level of biochemical blood parameters (CRP, creatinine, urea, glucose, total testosterone (T)); CT of the lungs. To objectify the severity of the clinical symptoms, the NEWS2 distress syndrome severity scales and the original scale for assessing the clinical condition of patients with COVID 19 (SHOCS-COVID) were used | ||
| 520 | |a RESULTS: The median T level in 152 examined patients was 2.14 [1.21; 3.40] ng/ml. In patients with a T level below the median, the CRP level was more than two times higher, and the D-dimer value was almost two times higher than in patients with T level above median. The duration of treatment in the hospital was longer in men with COVID 19 and an initial T level below the median than in patients with T about the median (13 days vs 10.5 days, p=0.003). Low T level was correlated with lung damage by lung CT. After improving the clinical condition, there was a linear increase in the level of T independent of its initial level | ||
| 520 | |a CONCLUSION: Among men with moderate and severe COVID-19, a decreased testosterone level is detected in 46.7% of cases. Patients with low testosterone levels on admission have more severe COVID-19. A significant increase in testosterone level was observed after successful COVID-19 treatment without any special action regarding testosterone level | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a NEWS2 | |
| 650 | 4 | |a SHOCS-COVID | |
| 650 | 4 | |a androgenic status | |
| 650 | 4 | |a testosterone | |
| 650 | 7 | |a Androgens |2 NLM | |
| 700 | 1 | |a Mareev, V Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Orlova, Ia A |e verfasserin |4 aut | |
| 700 | 1 | |a Ohobotov, D A |e verfasserin |4 aut | |
| 700 | 1 | |a Mareev, Yu V |e verfasserin |4 aut | |
| 700 | 1 | |a Begrambekova, Yu L |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlova, Z Sh |e verfasserin |4 aut | |
| 700 | 1 | |a Plisyk, A G |e verfasserin |4 aut | |
| 700 | 1 | |a Samokhodskaya, L M |e verfasserin |4 aut | |
| 700 | 1 | |a Mershina, E A |e verfasserin |4 aut | |
| 700 | 1 | |a Tretyakov, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Nesterova, O Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Shurygina, A S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologiia (Moscow, Russia : 1999) |d 1999 |g (2021), 6 vom: 01. Dez., Seite 85-99 |w (DE-627)NLM110630386 |x 1728-2985 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g number:6 |g day:01 |g month:12 |g pages:85-99 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |e 6 |b 01 |c 12 |h 85-99 | ||